JAB-BX300 / Jacobio Pharma - LARVOL DELTA

JACOS-B (01167): LIF monoclonal antibody JAB-BX300 clinical trial application approved in China [Google translation] (Zhitong Finance) - "Zhitong Finance APP News, Jiakesi-B (01167) issued an announcement that the group's self-developed LIF (leukemia inhibitory factor) monoclonal antibody JAB-BX300 received drug approval from the National Medical Products Administration (NMPA) on April 4, 2023. The Center for Evaluation (CDE) of the New Drug Clinical Trial Approval (IND) will carry out phase I/IIa clinical trials in advanced solid tumors in China."

New P1/2 trial • Oncology • Solid Tumor

Jacobio Pharma Announces 2022 Annual Results (PRNewswire) - "Jacobio has submitted the IND applications of JAB-BX300 (LIF mAb) to the NMPA in January 2023. The IND applications of JAB-23400 (KRASmulti inhibitor), JAB-30300 (P53 Y220C corrector) and JAB-26766 (PARP7 inhibitor) will be submitted this year."

New trial • Oncology

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83% (PRNewswire) - "...There are seven preclinical programs of Jacobio that are all new targets and are expected to submit IND applications as one of the first three globally. These include JAB-24114 (an undisclosed target in tumor metabolic pathway), JAB-BX300 (an undisclosed target in the RAS pathway), which is scheduled to submit an IND application in 2022, and JAB-26766...to submit an IND application during 2022 to 2023...JAB-23400 (KRASmulti inhibitor), JAB-22000 (KRAS G12D inhibitor), JAB-23000 (KRAS G12V inhibitor), JAB-30000 (P53 inhibitor) will submit IND applications during 2023 to 2024...Jacobio will submit a registrational clinical trial application for KRAS G12C inhibitor (JAB-21822) in China in 2022 and is expected to submit a New Drug Application (NDA) during 2023 to 2024..."

IND • New trial • Non-US regulatory • Oncology